BioSpace News Archive

Hepion Pharmaceuticals, Inc. today announced that, in addition to completing patient dosing in the 75 mg CRV431 cohort of its Phase 2a ‘AMBITION’ clinical trial, it has dosed the first NASH patient in the 225 mg CRV431 dosing cohort.

Expanded Capabilities of VISERA ELITE II Surgical Imaging Platform May Help Reduce Costs and Improve Efficiency for Hospitals and Surgery Centers

The systemic scleroderma treatment market is predicted to chart a notable growth trajectory over the forecast period from 2019 to 2029.

Transparency Market Research has published a new report titled, ‘Enteric Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.

Oblato, Inc., a wholly owned U.S. subsidiary of the Korean biotech company GtreeBNT Co., Ltd., announced it had official discussions with the FDA on a detailed plan for a phase 1/2 clinical trial to start developing a new treatment for Diffuse Intrinsic Pontine Glioma, a rare pediatric disease, using its proprietary drug, OKN-007.

COVID-19, first detected in China in late 2019 and has since been declared a pandemic, is posing both a serious threat to vulnerable populations and a challenge to the global economy.

- PDUFA Date of September 30, 2021 - NDA Filed Under FDA Accelerated Approval Program - Necrotizing soft tissue infection (NSTI) is a rare, life-threatening disease that involves significant necrosis and tissue destruction coupled with systemic organ failure - If approved, reltecimod would be the first therapy to treat suspected organ dysfunction or failure in patients with NSTI

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically i

PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (“PureTech” or the “Company”), today announced the initiation of a Phase 2a proof-of-concept study of LYT-100 (deupirfenidone) in patients with breast cancer-related, upper limb secondary lymphedema, a chronic and progressive disorder for which there are no FDA-approved drug therapies.

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 202